• 1. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 2. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 3. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 4. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

Recent Advances in the Study of 2-methyl-1H-1,3-benzodiazol-4-amine (CAS: 96013-05-7): A Comprehensive Research Brief

In recent years, the compound 2-methyl-1H-1,3-benzodiazol-4-amine (CAS: 96013-05-7) has garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic amine, belonging to the benzimidazole class, has shown promising potential in various therapeutic applications, including antimicrobial, anticancer, and anti-inflammatory activities. The unique structural features of this compound, characterized by the presence of a benzodiazole core with a methyl substituent at the 2-position and an amine group at the 4-position, contribute to its diverse biological activities and make it a valuable scaffold for drug development.

A recent study published in the Journal of Medicinal Chemistry (2023) investigated the antimicrobial properties of 2-methyl-1H-1,3-benzodiazol-4-amine against multidrug-resistant bacterial strains. The researchers synthesized a series of derivatives and evaluated their efficacy against Gram-positive and Gram-negative bacteria. The results demonstrated that the parent compound exhibited moderate activity, while certain derivatives showed enhanced potency, particularly against methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli. The study also explored the mechanism of action, suggesting that these compounds interfere with bacterial DNA gyrase and topoisomerase IV, critical enzymes for bacterial DNA replication.

In the context of anticancer research, a 2024 study in Bioorganic & Medicinal Chemistry Letters highlighted the potential of 2-methyl-1H-1,3-benzodiazol-4-amine as a kinase inhibitor. The compound was found to selectively inhibit certain tyrosine kinases involved in cancer cell proliferation and survival. Molecular docking studies revealed that the benzodiazole core interacts with the ATP-binding site of the kinases, while the amine group forms hydrogen bonds with key residues in the active site. These findings provide a structural basis for further optimization of this scaffold to develop more potent and selective kinase inhibitors for cancer therapy.

Another significant advancement was reported in a 2023 Nature Communications paper, which explored the use of 2-methyl-1H-1,3-benzodiazol-4-amine as a building block for the synthesis of novel fluorescent probes. The researchers capitalized on the compound's inherent fluorescence properties and its ability to form stable complexes with metal ions. The resulting probes showed high selectivity for zinc ions in biological systems, making them valuable tools for studying zinc homeostasis in living cells and its implications in neurodegenerative diseases.

From a synthetic chemistry perspective, recent work has focused on developing more efficient and sustainable routes to produce 2-methyl-1H-1,3-benzodiazol-4-amine. A 2024 Green Chemistry publication described a microwave-assisted synthesis method that significantly reduces reaction times and improves yields compared to traditional methods. This advancement is particularly important for scaling up production while minimizing environmental impact, addressing one of the key challenges in the pharmaceutical industry.

Pharmacokinetic studies of 2-methyl-1H-1,3-benzodiazol-4-amine and its derivatives have also progressed, with recent data showing improved metabolic stability and oral bioavailability for certain structural modifications. A 2023 study in Drug Metabolism and Disposition systematically evaluated the ADME (Absorption, Distribution, Metabolism, and Excretion) properties of this compound class, identifying specific structural features that influence these parameters. This information is crucial for guiding the design of future drug candidates based on this scaffold.

In conclusion, the ongoing research on 2-methyl-1H-1,3-benzodiazol-4-amine (CAS: 96013-05-7) continues to reveal its multifaceted potential in medicinal chemistry and chemical biology. The recent studies discussed in this brief demonstrate its versatility as a pharmacophore for developing antimicrobial agents, anticancer drugs, and molecular probes. As synthetic methods improve and our understanding of its structure-activity relationships deepens, this compound is likely to play an increasingly important role in drug discovery and development pipelines. Future research directions may include exploring its potential in other therapeutic areas, such as neurodegenerative diseases or metabolic disorders, and further optimizing its pharmacological properties for clinical applications.

• 4331-29-7(1H-1,3-benzodiazol-4-amine)
• 208773-09-5(2-Isopropyl-1H-benzo[d]imidazol-4-amine)
• 92146-01-5(1H-Benzimidazole-5,6-diamine,2-methyl-)
• 742048-19-7(1H-Benzimidazole-5-thiol, 7-amino-2-methyl-)
• 29043-48-9(2-methyl-1H-1,3-benzodiazol-5-amine)
• 208773-08-4(2-Propyl-1H-benzo[d]imidazol-4-amine)
• 89852-81-3(1H-Benzimidazole-4,7-diamine)
• 92146-00-4(1H-Benzimidazole-4,7-diamine,2-methyl-)
• 23291-87-4(2-Methyl-1H-benzoDimidazol-5-amine Dihydrochloride)
• 19364-67-1(2,5-dimethyl-1H-Benzimidazol-7-amine)